Nov 17, 2026

A Race Against Blindness Commits a Second $1 Million Gift to Advance Gene-Agnostic Therapeutic Approaches

Foundation News

The commitment directs $700,000 to the Gund Vision Fund, to be matched by the Gordon and Llura Gund Foundation as part of the Fund’s ongoing fundraising campaign, and $300,000 to a Foundation Fighting Blindness research award advancing a regenerative, gene-agnostic therapy

COLUMBIA, Md. and RALEIGH, N.C. – November 17, 2026 – The Foundation Fighting Blindness and its venture philanthropy arm, the Gund Vision Fund, today announced a second $1 million commitment from A Race Against Blindness, building on the partnership the organizations launched earlier this year, to advance gene-agnostic therapeutic approaches for inherited retinal diseases. The commitment directs $700,000 to the Gund Vision Fund and $300,000 to a Foundation Fighting Blindness research award. The Gordon and Llura Gund Foundation Challenge, a donor match that doubles new and increased gifts to the Fund, will match the $700,000 dollar for dollar, bringing the total impact to the Fund to $1.4 million.

The new commitment amplifies A Race Against Blindness’s initial $1 million gift earlier this year and reflects the continued generosity of the organization’s community of supporters. Founded in 2023 by Dr. Stephen Johnston and Kristina Johnston after their son was diagnosed with retinitis pigmentosa (RP) caused by Bardet-Biedl syndrome (BBS), the family-run nonprofit has directed millions of dollars toward research for RP and BBS, with a focus on pediatric inherited retinal diseases and on moving promising therapies from concept to clinic with urgency.

 Advancing Gene-Agnostic Approaches Across the Gund Vision Fund Portfolio

The $700,000 directed to the Gund Vision Fund will support gene-agnostic therapeutic approaches across the Fund’s portfolio, designed to benefit patients regardless of the underlying genetic cause of their disease. The Fund balances investments in gene-specific and gene-agnostic strategies, with portfolio companies pursuing neuroprotection to slow degeneration across all forms of RP, optogenetics-inspired approaches to restore light sensitivity, and cell therapies designed to restore function in surviving photoreceptors.

“This commitment from A Race Against Blindness, again matched through the Gordon and Llura Gund Foundation Challenge, allows us to grow and diversify a portfolio of gene-agnostic approaches that may benefit the greater RP community,” said Rusty Kelley, PhD, managing director of the Gund Vision Fund. “When partners reinvest, they help ensure that promising science continues moving closer to meaningful outcomes for patients.”

 Funding Regenerative, Gene-Agnostic Research at the Foundation Fighting Blindness

The remaining $300,000 commitment will advance gene-agnostic research through the Foundation Fighting Blindness preclinical science programs, and in particular the groundbreaking work of Dr. Jin Woo Kim at the Korea Advanced Institute of Science and Technology (KAIST). His research exemplifies the innovative approaches that have inspired A Race Against Blindness to expand its support for therapies with the potential to benefit patients across multiple forms of retinal disease.

Dr. Kim’s approach uses an antibody to inhibit the activity of PROX1, a protein that normally keeps Müller glia, the retina’s support cells, from regenerating. By inhibiting PROX1, the therapy enables Müller glia to reprogram into retinal progenitor–like cells, which are immature cells that can develop into new light-sensing photoreceptors. The goal is to induce regenerative capacity in the mammalian eye, which does not naturally repair itself after retinal damage. In animal models of RP, this approach has restored visual function. Because it works by promoting retinal repair through Müller glia reprogramming, it has the potential to help patients with many forms of RP regardless of the underlying mutation. The award will refine the antibody and its delivery and advance the most durable candidates toward large-animal studies and, ultimately, first-in-human trials, with potential application to other retinal degenerative diseases.

“Dr. Kim’s research represents the kind of innovative science that makes this an especially exciting time for the retinal disease community,” said Amy Laster, PhD, chief scientific officer of the Foundation Fighting Blindness. “We are grateful that A Race Against Blindness shares our enthusiasm and commitment to advancing a portfolio of promising approaches that could transform treatment for patients and families.”

“The continued innovative science at the Foundation and the Gund Vision Fund keeps us excited about what is possible in our partnership,” said Dr. Stephen Johnston, co-founder of A Race Against Blindness. “Dr. Kim’s regenerative research through the Foundation especially stood out to us, and we are glad our gift to the Fund also supports gene-agnostic approaches across its portfolio. These are the kinds of approaches that can help families like ours and so many others, whatever rare disease they are facing. We are all in this fight together, and we want to keep making an impact for as long as we can.”

As the world’s leading private funder of retinal degenerative disease research, the Foundation Fighting Blindness has played a key role in driving the development of more than 60 retinal disease drug candidates now in clinical trials, a track record that made it a natural partner for A Race Against Blindness.

About A Race Against Blindness
A Race Against Blindness is a family-run nonprofit co-founded in 2023 by Dr. Stephen Johnston and Kristina Johnston after their son was diagnosed with retinitis pigmentosa caused by Bardet-Biedl syndrome. Through innovative fundraising and a focus on pediatric inherited retinal diseases, the organization has directed more than $7 million toward research for retinitis pigmentosa and Bardet-Biedl syndrome, working to move promising therapies from concept to clinic with urgency. For more information, visit ARaceAgainstBlindness.org.

About the Foundation Fighting Blindness
Established in 1971, the Foundation Fighting Blindness is the world’s leading private funding source for retinal degenerative disease research. The Foundation has raised nearly $1 billion toward its mission of accelerating research for preventing, treating, and curing blindness caused by the entire spectrum of retinal degenerative diseases, including retinitis pigmentosa, age-related macular degeneration, Usher syndrome, and Stargardt disease. Visit FightingBlindness.org for more information.

About the Gund Vision Fund
The Gund Vision Fund is the venture philanthropy arm of the Foundation Fighting Blindness and a 501(c)(3) not-for-profit subsidiary. Launched in 2018 as the first and only fund solely dedicated to advancing therapeutics for inherited retinal diseases and dry age-related macular degeneration, the Fund bridges the critical funding gap between discovery-stage research and drug development. For more information, visit GundVisionFund.org.

###

Media Contact:
Chris Adams
Vice President, Marketing & Communications
CAdams@FightingBlindness.org
410-423-0585